Loading the session
Loading the session
Loading instrument
$47.88
+0.00%Delayed · Pre-marketDelayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 16:00 IST · A quote does not mean the product is available to trade on your account.
Opens 8:00 pm IST
Opens 8:00 pm IST
Opens 8:00 pm IST
In brief
Questions investors ask
Quotes run fifteen minutes behind.
1 month: +34.2% (SPY −1.6%, XLV +13.5%). 3 months: +23.5% (SPY −0.4%, XLV +15.5%). 1 year: +146.0% (SPY +13.6%, XLV +30.7%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: SEPN, SPY and XLV · as of 4 Nov 2026
Closed at $47.88 on 4 Nov 2026: 6.3% below the 52-week high of $51.10 (12 Aug 2026) and 172.8% above the low of $17.55 (7 Nov 2025).
Daily price bars, split-adjusted · as of 4 Nov 2026
3.5M shares were sold short at the 15 Oct 2026 settlement; covering them would take 7.6 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026
The 4 Nov 2026 close of $47.88 was 22.1% above its 50-day average ($39.21) and 48.0% above its 200-day average ($32.35). It has closed above the 200-day for 296 sessions, since 3 Sep 2025. The 50-day average crossed above the 200-day on 11 Sep 2025, 289 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
The 14-session relative strength index closed at 72.2 on 4 Nov 2026, its 1st session at 70 or above. By convention a reading of 70 or above is called overbought and 30 or below oversold.
Daily closes, split-adjusted; Wilder's 14-session RSI · as of 4 Nov 2026
Price return, split-adjusted
At the 4 Nov 2026 close
Septerna Inc is a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by a proprietary Native Complex Platform. Its industrial-scale platform aims to unlock the full potential of GPCR therapies. The group discovery and development of a pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic disease. Its pipeline includes SEP-786 (PTH1R), SEP-631 (MRGPRX2), TSHR, GLP-1R, GIPR, and GCGR.
August 11, 2026
+22.93%May 14, 2025
+50.97%February 18, 2025
−46.99%